Login for students

Login for employees

Publication detail

Pulmonary Arterial Hypertension in a Patient with Multiple Sclerosis Treated with Interferon Beta: A Case Report
Authors: Novotná Alena | Ehler Edvard | Mandysová Petra | Jansa Pavel
Year: 2016
Type of publication: článek v odborném periodiku
Name of source: Journal of Neurology and Neuroscience
Page from-to: 72-74
Titles:
Language Name Abstract Keywords
cze Plícní arteriální hypertenze u nemocného s roztroušenou sklerózou léčeného interferonem beta: kazuistika. Pozadí: Plicní arteriální hypertenze (PAH) je charakterizována elevací středního plicního arteriálního tlaku, který se blíží systémovému tlaku. PAH je spojena se špatnou prognózou. Rozvoj PAH je způsoben mnoha faktory a jednám z nich je i farmakoterapie. Kazuistika: 39-letá žena léčena pro relabující-remitující roztroušenou sklerózu (MS) byla po 10 let léčena interferonem beta. Při zjištění PAH byla léčba interferonem beta ukončena, vzhledem k pravděpodobnosti další progrese PAH. Vzhledem k tíži PAH byla zahájen specifická farmakoterapie (sildenafil). V literatuře se od r.1998 popsalo několik kazuistik nemocných léčených interferony, u kterých se vyvinula PAH, z nich 2 byli léčeni pro MS Závěr: Rozvoj PAH byl v důsledku dlouhodobé léčby interferonem beta. roztroušená skleróza; plicní arteriální hypertenze; Interferon Beta sildenafil
eng Pulmonary Arterial Hypertension in a Patient with Multiple Sclerosis Treated with Interferon Beta: A Case Report Pulmonary arterial hypertension (PAH) is characterized by elevation of mean pulmonary artery pressure to values conceivably approaching those seen in the systemic vascular bed. This occurrence is associated with a poor prognosis. PAH may result from a variety of causes, some of which are related to pharmacotherapy. Herein, we present a case of a 39-year-old female patient with relapsing-remitting multiple sclerosis (MS), who was receiving immunomodulatory therapy and subsequently developed severe PAH. We presume a causal relationship between the condition and the patient’s interferon beta therapy, which had spanned 10 years. The interferon beta therapy was stopped because its continued administration could have led to more rapid progression of severe pulmonary hypertension. Due to the severity of pulmonary arterial hypertension, PAH-specific pharmacotherapy was indicated, using sildenafil. Since 1998, only several cases of pulmonary arterial hypertension in patients treated with interferon beta have been documented in the scientific literature. In some of these instances, including in two case studies involving patients with multiple sclerosis, it was concluded that there was a possible association with this therapy. Multiple sclerosis; Pulmonary arterial hypertension; Interferon beta sildenafil

Departments

Clinics

Map

en.mapy.cz

Services

Popular Links

© 2023 University of Pardubice, Studentská 95, 532 10 Pardubice 2
Phone: +420 466 036 111, 466 036 112, 466 036 113
Webmaster, RSS
Data box ID: f5vj9hu
Accessibility Statement
CC BY-NC-ND 4.0Creative CommonsAttributionNonCommercialNoDerivatives